Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the recipient of a large drop in short interest during the month of June. As of June 15th, there was short interest totalling 570,200 shares, a drop of 35.3% from the May 31st total of 881,100 shares. Currently, 4.5% of the company’s shares are short sold. Based […]
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the recipient of a large decline in short interest in June. As of June 15th, there was short interest totalling 570,200 shares, a decline of 35.3% from the May 31st total of 881,100 shares. Based on an average daily trading volume, of 5,430,000 shares, the short-interest ratio […]
Navidea Biopharmaceuticals, Inc. (NYSE:NAVB – Free Report) was the target of a significant decline in short interest during the month of June. As of June 15th, there was short interest totalling 570,200 shares, a decline of 35.3% from the May 31st total of 881,100 shares. Based on an average daily volume of 5,430,000 shares, the […]
StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Free Report) in a research report sent to investors on Tuesday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Stock Performance Shares of NYSEAMERICAN:NAVB opened at $0.09 on Tuesday. The business’s 50 day simple moving average is $0.13 and its […]
StockNews.com initiated coverage on shares of Navidea Biopharmaceuticals (NYSEAMERICAN:NAVB – Free Report) in a research report released on Sunday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Navidea Biopharmaceuticals Stock Performance NYSEAMERICAN NAVB opened at $0.09 on Friday. The firm has a 50 day simple moving average of $0.14 and a […]